The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Masciopinto, Pierluigi; Dell’Olio, Grazia; Robertis, Rosa De; Specchia, Giorgina; Musto, Pellegrino; Albano, Francesco

doi:10.3390/jcm9113403

Cited by 9 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Autoimmune conditions have been defined as a risk factor for the development of lymphoma, and the use of immunosuppressive medications is thought to play a significant role. 9 The clinical course of CLL/SLL can differ greatly between patients. While some can live for many years, others may experience rapid disease progression and death within 2 to 3 years after diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study

Nanni

2023

Journal of Diagnostic Medical Sonography

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing cancers that affect the immune system by disrupting the normal function of B-cells. The patient symptoms associated with CLL and SLL can be vague; therefore, many cases go undiagnosed for years. Diagnostic medical sonography is an imaging technique that can determine the abnormal appearance of lymph nodes and guide medical providers in the appropriate direction when investigating a questionable case of lymphoma. This case study presents a superficial left-neck sonogram of a 65-year-old Caucasian man complaining of left supraclavicular pain and swelling. This initial sonogram was the first phase in a sequence of examinations that led to the patient’s diagnosis of CLL/SLL.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study

Nanni

2023

Journal of Diagnostic Medical Sonography

View full text Add to dashboard Cite

show abstract

“…Factors contributing to this risk include underlying immune changes associated with autoimmunity and immunosuppression used to treat the disease. 146 Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases, and there is a strong association with an increased risk of lymphoma in these patients. 144 A recent meta-analysis of LPDs in patients with rheumatoid arthritis showed 54% of all RA-associated LPDs were EBVpositive.…”

Section: Dev E Lopm E N T Of Ebv-as Soci Ate D L Pds I N Patie N Ts W...mentioning

confidence: 99%

“…Patients with autoimmune disease have an increased risk of developing LPDs, many of which are EBV‐associated. Factors contributing to this risk include underlying immune changes associated with autoimmunity and immunosuppression used to treat the disease 146 . Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases, and there is a strong association with an increased risk of lymphoma in these patients 144 .…”

Section: Development Of Ebv‐associated Lpds In Patients With Autoimmu...mentioning

confidence: 99%

Epstein–Barr virus‐associated lymphomas decoded

Bednarska,

Chowdhury,

Tobin

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryEpstein–Barr virus (EBV)‐associated lymphomas cover a range of histological B‐ and T‐cell non‐Hodgkin and Hodgkin lymphoma subtypes. The role of EBV on B‐cell malignant pathogenesis and its impact on the tumour microenvironment are intriguing but incompletely understood. Both the International Consensus Classification (ICC) and 5th Edition of the World Health Organization (WHO‐HAEM5) proposals give prominence to the distinct clinical, prognostic, genetic and tumour microenvironmental features of EBV in lymphoproliferative disorders. There have been major advances in our biological understanding, in how to harness features of EBV and its host immune response for targeted therapy, and in using EBV as a method to monitor disease response. In this article, we showcase the latest developments and how they may be integrated to stimulate new and innovative approaches for further lines of investigation and therapy.

show abstract

“…Of note, T cell lymphopenia is a distinct characteristic in the ADs associated with T-cell PID disorders such as WAS [ 130 , 131 ]; however, despite its association with a variety of ADs as shown in Table 1 , T cell lymphopenia may not be present in patients who are suffering from ADs [ 132 , 133 ] due to enduring LIP and/or the concomitant occurrence of other lymphoproliferative conditions such as lymphomas [ 134 , 135 ]. It has been shown that this concomitant occurrence of lymphoproliferative conditions might be linked to treatment with methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD) [ 136 , 137 , 138 ].…”

Section: Lymphopenia In Physiological and Autoimmune Conditionsmentioning

confidence: 99%

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity

Sheu

Chiang

2021

IJMS

View full text Add to dashboard Cite

Immune homeostasis is a tightly regulated system that is critical for defense against invasion by foreign pathogens and protection from self-reactivity for the survival of an individual. How the defects in this system might result in autoimmunity is discussed in this review. Reduced lymphocyte number, termed lymphopenia, can mediate lymphopenia-induced proliferation (LIP) to maintain peripheral lymphocyte numbers. LIP not only occurs in normal physiological conditions but also correlates with autoimmunity. Of note, lymphopenia is also a typical marker of immune aging, consistent with the fact that not only the autoimmunity increases in the elderly, but also autoimmune diseases (ADs) show characteristics of immune aging. Here, we discuss the types and rates of LIP in normal and autoimmune conditions, as well as the coronavirus disease 2019 in the context of LIP. Importantly, although the causative role of LIP has been demonstrated in the development of type 1 diabetes and rheumatoid arthritis, a two-hit model has suggested that the factors other than lymphopenia are required to mediate the loss of control over homeostasis to result in ADs. Interestingly, these factors may be, if not totally, related to the function/number of regulatory T cells which are key modulators to protect from self-reactivity. In this review, we summarize the important roles of lymphopenia/LIP and the Treg cells in various autoimmune conditions, thereby highlighting them as key therapeutic targets for autoimmunity treatments.

show abstract

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Cited by 9 publications

References 38 publications

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study

Epstein–Barr virus‐associated lymphomas decoded

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity

Contact Info

Product

Resources

About